 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...2829303132333435363738...858859» |
- Krystexxa (pegloticase) / Amgen
The Relationship Between Anti-drug Antibodies, Infusion Reactions, and Loss of Urate-lowering Response in Patients with Uncontrolled Gout Treated with Pegloticase (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2610;
Consistent with prior study,1 anti-uricase Abs did not seem to influence pegloticase safety or efficacy. These results further support a negative correlation between pegloticase concentrations and anti-PEG Ab titers, as well as elevated titers, in those experiencing LOR or an IR.
- Krystexxa (pegloticase) / Amgen
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2608;
P4
Pegloticase treatment over 6-12 months markedly improves uncontrolled gout signs/symptoms2,3 and patient quality of life.4 However, biweekly 2-hr infusions can be challenging for patients. Safety/efficacy data from the AGILE trial, support shortening infusion time to 60-min to minimize patient treatment burden.
- Krystexxa (pegloticase) / Amgen
Race, Ethnicity, and Rheumatology Care Predict Long-term Urate-Lowering Treatment Persistence Following a Treat-to-Target Intervention in a Large, Multicenter Randomized Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2597;
The issue of limited treatment durability appears to be compounded among underrepresented patient populations and improved in the context of rheumatology subspecialty care. These results suggest the need for interventions specifically designed to facilitate continued treatment maintenance following initial successful implementation of T2T ULT in gout management.
- Krystexxa (pegloticase) / Amgen
Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2590;
Measurement of PUA at 24 hours and 2 weeks post initial treatment provides information that can predict persistent urate lowering in patients with chronic uncontrolled gout. Weight is associated with 24 hr PUA levels, suggesting that weigh-based dosing could be useful to increase responsiveness to pegloticase.
- Krystexxa (pegloticase) / Amgen
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2584;
The Phase I clinical trial data indicated that PU5 is safe in healthy humans and has promising PK/PD and immunologic characteristics. More detailed information about PU5, including its amino acid sequence, preparation and characterization, pre-clinical PK/PD data, and Phase I clinical data, will be presented at the meeting.
- Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2565;
There was a lack of consensus regarding when to use GC tapering and for how long to keep patients on maintenance therapy. While the education provided had a robust impact on knowledge and confidence, these findings highlight the need for subsequent education regarding evidence-based practices for patient assessment and how to incorporate steroid-sparing regimens into practice.
- Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2542;
For patients with these risk factors, abatacept or tocilizumab may be considered as preferred options. These findings underscore the need for careful monitoring and tailored therapeutic strategies to enhance patient outcomes.
- Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2536;
The results indicate that the risk of malignancies did not exhibit statistically significant differences among Asian RA patients treated with csDMARD-only, JAKi, and other bDMARD regimens, except for a potential association of rituximab with a lower incidence. However, it's important to note that regular cancer screenings are still advisable for these patients while they are undergoing JAKi/biologic treatment.
- Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2511;
Switching of originator biological therapies to its biosimilar in our cohort of patients might not have an impact on efficacy or the incidence of infections; however, one of the most common AEs was associated with the mechanics of the autoinjector device. Although this may seem a minor issue, it led to patients missing a dose, thus having an impact on treatment compliance and thus the activity of the disease.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2502;
However, the cost reduction came at the expense of a higher flare rate in the taper group especially in the subset of patients tapering their biologic therapy. We plan to expand our cohort to a multicenter study to analyze clinical outcomes and costs of methotrexate tapering strategies, and to identify biomarkers predictive of successful tapering.
- Humira (adalimumab) / AbbVie
Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2495;
1.0 mg/L were switched to a non-TNFi b/tsDMARD...In both groups the specific non-TNFi b/tsDMARD, chosen at the discretion of the treating physician, could be abatacept, rituximab, sarilumab, tocilizumab, or a Janus kinase inhibitor... A switching strategy based on adalimumab trough serum concentration was not superior to random switching in RA patients failing adalimumab treatment.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2420;
This study developed predictive models for axSpA flares in patients treated with b/tsDMARDs, using machine learning and data from the METEOR-SpA registry. The reduced logistic regression model, identified history of enthesitis, history of flares, longer treatment duration and lower ASDAS as predictors for disease flares.
- Rinvoq (upadacitinib) / AbbVie
Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2348;
UPA pts also had greater rates of remission at 3 months compared to TNFi and other JAKi. Overall, this suggests a favourable UPA clinical profile in RA patients.
- Enbrel (etanercept) / Pfizer, Amgen
Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2322;
Overall, this suggests a favourable UPA clinical profile in RA patients. Our findings indicate that the models based on proteomic signatures accurately predict response before ETN treatment, paving the path toward personalized anti-TNF treatment.
- Risk of Malignancy with TNF-? Inhibitors in Patients with Rheumatoid Arthritis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2284;
inhibitors are at an increased risk of cancer compared to those on non- TNF-? inhibitors which includes both conventional and other biological DMARDs.
- zetomipzomib (KZR-616) / Kezar
Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2229;
P1/2
inhibitors which includes both conventional and other biological DMARDs. Results from this subgroup analysis suggest that treatment with zetomipzomib 60 mg once weekly is effective across multiple organ systems in patients with highly active SLE as well as in those with nephrotic range proteinuria (UPCR ?3).
- Enbrel (etanercept) / Pfizer, Amgen, Cosentyx (secukinumab) / Novartis
Uveitis in Axial Spondyloarthritis: Study of 309 Patients in a Single University Center (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2163;
Most patients with uveitis had positive HLA-B27 and severe sacroilitis in x-ray was more frequent. The most frequent pattern of uveitis observed in axSpA was acute, anterior and unilateral.
- Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2149;
In this meta-analysis of RCTs, no significant difference has been found in the effect of bDMARDs vs PBO in early compared to established axSpA, defined according to several thresholds of symptom duration (between 2 and 5 years). Treating patients earlier or later in the disease course translates into the achievement of comparable short-term clinical outcomes.
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2005;
Our 3D RA synovial tissue effectively replicates alterations in cellular interactions based on macrophage phenotype and demonstrates the inhibitory effects of therapeutic compounds on spheroid outgrowth and soluble mediator production. This model shows the potential for testing the effect of various therapeutic applications on RA synovial inflammation and angiogenesis.
- Cimzia (certolizumab pegol) / Astellas, UCB
Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1956;
P4
RF binding to ADA drove protein complex formation, which stimulated macrophage mediated protein complex clearance. These findings provide insights into why CZP efficacy is independent of patient RF level, while patients with RA and high RF levels, exhibit reduced serum drug concentrations and treatment outcomes when treated with Fc-containing bDMARDs, compared to those patients with lower RF levels.
- DC-9476 / DeepCure
DC-9476, a Novel Selective BRD4(BD2) Inhibitor, Improves Arthritis Scores in Preclinical Models of Rheumatoid Arthritis by Regulating Key Inflammatory Pathways (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1791;
We demonstrate that the selectivity for a single BET protein and bromodomain of DC-9476 resulted in favourable anti-inflammatory effects in murine RA models and reduced BET inhibitor-related toxicities. These data indicate that DC-9476 could be a novel class of BET inhibitor for treating RA and warrants the assessment of DC-9476 in ex vivo models derived from active RA patients.
- Zurampic (lesinurad) / AstraZeneca, Krystexxa (pegloticase) / Amgen, Ilaris (canakinumab) / Novartis
Are Participants in Gout Clinical Trials Representative of People with Gout in the General Population? (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1757;
Clinical trials of gout medications approved by the FDA since 2009 have not enrolled a study population that is representative of the US population with gout, based on demographic features and cardiometabolic comorbidities. For broader applicability to the general population with gout, future phase 3 trials should ensure representative inclusion of women, older individuals, diverse ethnicities, and those with comorbid health conditions that are commonly experienced by people with gout.
- Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1726;
The associations were consistent across various exposure periods. Further studies on larger cohorts are needed to confirm the results.
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Social Determinants of Health in Osteoporosis Treatment Patterns Among Adults with Rheumatoid Arthritis and Major Osteoporotic Fracture in the All of Us Research Program: A Cross-Sectional Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1642;
Further studies on larger cohorts are needed to confirm the results. Participants were classified as osteoporosis-treated if they received any prescription for a bone health pharmacologic therapy (oral or IV bisphosphonate, denosumab, raloxifene, abaloparatide, teriparatide, or romosozumab) at any time; otherwise, a participant was treatment-na
- Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1613;
There is a lack of high quality evidence to support recommendations for non-elective, non-orthopaedic surgery cases. Variations in recommendations were more common for csDMARDs compared to b/tsDMARDs, potentially leading to more practice variation in csDMARD use in the perioperative period.
- Humira (adalimumab) / AbbVie
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1590;
Early indications are that formulary coverage has been uneven with a much higher percentage of formularies covering bio-originator adalimumab and no formularies have given a biosimilar a preferential tier or mandated step therapy. Delayed uptake of biosimilars means reduced savings for patients and tax payers, and discourages market entry for future biosimilars.
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1578;
Medicare beneficiaries billing romosozumab under Part D faced increased discontinuation risk after adjusting for comorbidities, healthcare utilization, and SES factors, particularly in the early treatment period. These findings highlight the need for streamlined healthcare delivery processes and targeted support for timely access to medication among postmenopausal women with OP.
- Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1576;
Moreover, the evaluation of trends revealed a significant increase in the annual treatment costs of TNFi bDMARDs. The FDA authorization of biosimilars significantly reduced the annual cost of bDMARDs used in RA treatment.
- Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1463;
Using the Trinetx database, we identified five different cohorts for each of the TNF inhibitors, excluding patients on other TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, and golimumab). Compared to prior reports of a higher risk of developing demyelinating disease with etanercept, our study showed that patients on etanercept do not have an increased risk of demyelinating disease compared to other TNF inhibitors, while infliximab has a statistically significant higher risk compared to adalimumab.
- Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022 (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1409;
Among b/tsDMARDs, adalimumab is now the most widely used and the predominant b/tsDMARD started first after csDMARDs. Patterns in DMARD use for JIA have evolved relative to multiple factors, including pediatric regulatory approvals and tolerability.
- Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1402;
Enrollment for the main trial and ancillary studies are robust across sites. Stakeholder-partner designed recruitment materials are influential in a family's decision to enroll.
- Prolia (denosumab) / Amgen
Providing Optimal and Equitable Osteoporosis Treatment Using a Programmatic Approach -A 20 Year Longitudinal Study (Room 207AB; In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1303;
The osteoporosis clinic care was superior to the PCPs and specialty clinic. Treatment was equitable independent of insurance or race.
- Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Humira (adalimumab) / AbbVie
Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1288;
Analytical performance of all tested parameters demonstrated equivalency. Therefore, clinicians can confidently use the originator ADL tests to monitor drug levels and ADA titers in patients on the biosimilar adalimumab-atto.
- prednisone / Generic mfg.
Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1252;
Clinical factors of obesity, prednisone use, and not concurrently taking methotrexate during treatment with a first-line b/tsDMARD were predictive of becoming D2T, along with patient reported outcomes of greater fatigue and disease activity. Future studies should evaluate risk factors for subphenotypes of inflammatory and non-inflammatory D2T-RA.
- Enbrel (etanercept) / Pfizer, Amgen
A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways (Room 206; In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1200;
We have designed a novel CSF-1R agonist optimized for sustained receptor activation and tissue macrophages reprogramming to promote expression of inflammation resolution and tissue remodeling functions. Tissue macrophages activation was decoupled from pro-inflammatory monocytes tissue infiltration induction that may be a beneficial property for the treatment of chronic inflammatory conditions.
- Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study (Room 150AB; In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1011;
Patients on TNFi also had lower urea nitrogen and BNP levels as well as a better LV function when compared with patients not TNFi. Further research is needed to better understand the effects and mechanisms of these medications in patients with CS
- Tavneos (avacopan) / Amgen
Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs (Room 202AB; In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1007;
Rather, non-IFN related transcriptional events associate with damage including C5aR and ITGA11. These results suggest novel useful biomarkers and potential therapeutic targets for LN (eg.
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings (Room 144ABC; In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_901;
P3
Corticosteroids were normalized to 20 mg/day prednisone at the time of randomization and were tapered to discontinuation at the end of study Week 8. The MITIGATE trial, the first randomized, double-blind, placebo-controlled study ever conducted in IgG4-RD, establishes the safety and efficacy of CD19-targeted B cell depletion with inebilizumab in IgG4-RD.
- || xaluritamig (AMG 509) / Amgen
New P1 trial: Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer (clinicaltrials.gov) - Sep 25, 2024
P1, N=30, Not yet recruiting, Sponsor: Amgen
- ||||| rocatinlimab (KHK4083) / Amgen
Enrollment closed: ROCKET-ASTRO: A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (clinicaltrials.gov) - Sep 25, 2024
P3, N=532, Active, not recruiting, Sponsor: Amgen
The MITIGATE trial, the first randomized, double-blind, placebo-controlled study ever conducted in IgG4-RD, establishes the safety and efficacy of CD19-targeted B cell depletion with inebilizumab in IgG4-RD. Recruiting --> Active, not recruiting
- |||| Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
New P4 trial: ARRIA: Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis (clinicaltrials.gov) - Sep 24, 2024
P4, N=160, Not yet recruiting, Sponsor: Chiba University
- | Stivarga (regorafenib) / Bayer, botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
Enrollment closed, Enrollment change: Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients with Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (clinicaltrials.gov) - Sep 24, 2024
P1/2, N=28, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=63 --> 28
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Clinical, Journal: Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study. (Pubmed Central) - Sep 24, 2024
In real-world scenarios, despite the study's limitations, our results underscore Tezepelumab's promise as a therapeutic option for uncontrolled severe asthma, and may be useful for non-responders to other mAbs. Further studies are needed to corroborate these findings.
- | Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Journal: Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis. (Pubmed Central) - Sep 24, 2024
Meanwhile, we established that GTF2I is dephosphorylated at S784 via ERK by KRAS inhibitors, which hinders its nuclear translocation and mediates ALDH1A1's upregulation in response to KRAS inhibitors. In summary, the results offer valuable insights into targeting ALDH1A1 to enhance the effectiveness of KRAS-targeted therapy through ferroptosis in cancer treatment.
- Jakafi (ruxolitinib) / Incyte, Keytruda (pembrolizumab) / Merck (MSD), Enbrel (etanercept) / Pfizer, Amgen
Steroid Refractory Acute Liver Graft-versus-Host Disease Rescued By Parenteral Vitamin C, A Case Report and Perplexity AI Explorative Application (Exhibition Hall (3F)) - Sep 24, 2024 - Abstract #ICBMT2024ICBMT_325;
By AI, parenteral vitamin C could be considered as an adjunctive therapy in this challenging liver GVHD. Conclusions : AI promts with precise sequential clinical scenario are applicable solutions in steroid refractory aGvHD.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Efficacy and Safety of Salvage Chemotherapy Regimens in Relapsed or Refractory Acute Myeloid Leukemia (Room A (2F)) - Sep 24, 2024 - Abstract #ICBMT2024ICBMT_86;
Conclusions : AI promts with precise sequential clinical scenario are applicable solutions in steroid refractory aGvHD. In this regard, we compared the efficacy and safety of salvage regimens
- Nplate (romiplostim) / Amgen
From Second-Line to First-line: The Evolving Role of Romiplostim in Severe Aplastic Anemia Management (Room D-1 (1F)) - Sep 24, 2024 - Abstract #ICBMT2024ICBMT_40;
In this regard, we compared the efficacy and safety of salvage regimens Sponsored by Kyowa Kirin Korea
- Nplate (romiplostim) / Amgen
[LS04] Luncheon Symposium 4 (Kyowa Kirin Korea): Efficacy and Safety of Romiplostim in First-Line Treatment of Severe Aplastic Anemia (Room D-1 (1F)) - Sep 24, 2024 - Abstract #ICBMT2024ICBMT_39;
Sponsored by Kyowa Kirin Korea Sponsored by Kyowa Kirin Korea
- Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Real-World Experiences of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (Room A (2F)) - Sep 24, 2024 - Abstract #ICBMT2024ICBMT_7;
Conclusions : Our data suggested that INO can be a feasible choice for salvage for adults with R/R BCP-ALL which showed a good CR rate. However, we experienced unexpectedly high regimen-related toxicity.
- Blincyto (blinatumomab) / Astellas, Amgen
Korean Real-World Experience of Blinatumomab for 8 Years Regarding Predictive Factors Including Lymphocyte Kinetics for Response and Survival Outcome in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (Room A (2F)) - Sep 24, 2024 - Abstract #ICBMT2024ICBMT_6;
The standard protocol consisted of pre-phase dexamethasone, first cycle blinatumomab 28-days (9mcg during initial 7d followed by 28mcg for 21d) was followed by 2-week resting period and second or more cycle of 28mcg blinatumomab for 28-days...We observed early relapse with short CR duration, PB blast prior to blinatumomab, and later-line salvage were related with poor response to blinatumomab and old age and early relapse for poor OS even after allo-HCT. Regarding absolute lymphocyte count (ALC), ALC at first day of blinatumomab was not significantly affecting the response and outcome, but we observed ALC2000/mcL at 2-weeks after blinatumomab was predictive for poor response and poor survival Conclusions : Our long-term data showed blinatumomab was effective even with low ALC before blinatumomab, but preserved ALC was related with good response and better survival outcome.